Long for a Longtime or until they make me an offer I cant' Refuse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From a service I follow..
Reviewed 06-16-2016 “AVXL” a swing & Value play ~1500/3000-shares at $3.00 and or a drop below $3.55 and a subsequent rebound back above $3.55 or we break out > $4.20 target $8.95 then $12.95 SL=0.30+/- Potential take out play..... Forward P/E = N/A P/S = N/A Short-Interest = 4.00%, Float = 28.00 million Cash on hand = 0.26 $165,000 DEBT Its Optionable Anavex presents positive safety and cognitive efficacy data for ANAVEX 2-73; study met the primary objective of safety AVXL presented positive safety and cognitive efficacy data for ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's disease targeting sigma-1 and muscarinic receptors.
Great Point!
The recent improvement in diagnostics will also help to streamline Anavex trials
Imagine spending all that $$$$ on developing a drug and along comes a small biotech company (small printing firm) that has a drug the will make your drug obsolete before you get it to market... I am loving this...
Here is the video... Anavex has the stronger showing IMHO http://aca.ninemsn.com.au/article/9131446/alzheimers-drug
The Retts Phase 2 PR may come next week. If funding is announced with the PR the PPS should benefit. You can always cost average.
George is just anticipating next weeks PR...IMO
Regardless of the approval outcome, this receptor chemistry science is crucial to modern medicine.
I couldn't agree more.... let the perfect machine do its thing..just a matter of learning the switches
Sorry sir we turned you into a smurf...
I guess I anoyed them enough....http://www.anavex.com/?events=2016-rett-syndrome-symposium
That's what I am thinking..
I have emailed IR twice asking why the Retts conference was not posted on the website....no response....Hopefully we see a PR about Phase 2 Retts study along with funding from the organization.
The group seems to have multiple outlets.
A paid for PR!
Annavex Life Sciences (NASDAQ: AVXL) is among the more recent companies that have had to do a reverse stock split. The company effected a 1-4 reverse split back in October last year and also uplisted to NASDAQ. Although the clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer has not been able to get back to its post IPO highs of almost $13 per share, the stock still has plenty of room for growth.
Just last week, the company disclosed that the FDA had granted Orphan Drug Designation to its ANAVEX 2-73 for the treatment of Rett syndrome a clear signal of more upside potential in the stock. Rett syndrome is a devastating disease occurring in early childhood and almost exclusively in girls and since there is currently no cure, ANAVEX stands to become the standard of care in the near term.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
Good attitude... I still think the odds are in our favor....don't let the crooks shake you out.
FB group is wrong
New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
Metro Toronto Convention Centre Room: Hall D/E
P1-046
9:30am - 10:30am
Sun, Jul 24....This is the 2016 conference
I hope so.. I have stopped trying to predict....the most I can do is speculate
Let the games begin!
Run up to July conference will be fun to watch.
Don't let the crooks take your shares.
Finally filled that 5/20 gap @ 4.17.... this stock has always filled the gaps.
I also think this was used as a place holder... We should know within a couple of weeks.
Stephen Macfarlane is listed as a speaker.
New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
Not bad for a printing company!
Great post and thanks.
You can add clearing of law suits and SEC investigation.
Really!
I don't believe you based on your posts and I look forward to the day the Good Doctor makes all you shorts pay the price.
Is that what the cabal wants....the good doctor may spoil your party/
Has anyone considered that the Good Doctor has turned down offers waiting to get his ducky's in a row. Just a thought and could be the reason they continue to attack the company with BS articles and those angry MM's.
No problem with that.... more exposure and credibility for the Good Doctor and Anavex...
We would be very interested in continuing the work with ANAVEX 2-73,” said Michael Tranfaglia, MD, Medical Director, Chief Scientific Officer of FRAXA Research Foundation.
http://www.fraxa.org/research-funded-2015/
I find that hard to believe...the models for the studies have to be different.
Psoriasis...AD apples and oranges
I am always amazed at the TV drug ads that tell you the many ways a particular drug can kill you. How the hell do these drugs get approved by the FDA? Answer is always ....Follow the $$$$$$$.
This would be a perfect time and place to announce the phase 2 study for Retts with help from Rettsyndrome.org
http://www.rettsyndrome.org/research-programs/rett-syndrome-symposium-2016
George,
As always a great find...keep up the good work.
Thanks for your input from an old timer and long time long.
I agree with your points and I also found it interesting that this meeting was announced quite a while ago...not what they normally do.. based on the timing I thought this would be the 26 week data announcement....but what the hell do I know.
I find it interesting that an abstract has not been publish for this conference.... the mystery continues...GLTAL
Got a 420 close just for you...lol